Kristina A Giles1, Eva M Rzucidlo1, Philip P Goodney1, Daniel B Walsh1, Richard J Powell2. 1. Section of Vascular and Endovascular Surgery, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 2. Section of Vascular and Endovascular Surgery, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: richard.j.powell@hitchcock.org.
Abstract
OBJECTIVE: Bone marrow cell therapy (BMCT) for patients with critical limb ischemia (CLI) is a potential treatment in candidates with poor options for standard revascularization procedures. Whereas clinical trials are ongoing, there are few comparative data to assess its efficacy compared with bypass. METHODS: Patients with poor revascularization options underwent BMCT between 2011 and 2013. Outcomes were compared with those of a cohort of CLI patients undergoing infrainguinal bypass thought to be at high risk for graft failure (tissue loss, a tibial target, and a previous endovascular treatment or bypass). BMCT patients underwent harvest of bone marrow that was then concentrated and injected intramuscularly into the ischemic limb. RESULTS: There were 20 BMCT patients and 35 high-risk bypass patients. All BMCT patients had either rest pain (80%) or tissue loss (80%). The majority (65%) had a prior intervention (bypass, 30%; endovascular, 58%) compared with high-risk bypass patients, all of whom had previous revascularization attempts (bypass, 43% [P = .35]; endovascular, 77% [P = .14]). Mean follow-up was 773 days after BMCT and 972 days after high-risk bypass. All patients tolerated BMCT without issues or complications. A second BMCT treatment was performed in 21% because of clinical deterioration. Wound healing occurred in 75% at 1.5 years, including patients receiving second injections, all of which resolved. Rest pain improved in 87.5% of patients. Pain completely resolved in 58% at 1.5 years. Ankle-brachial index improvement was 0.23 (±0.25). Three BMCT patients went on to amputation. One-year freedom from major amputation or death was 78% for BMCT vs 69% for high-risk bypass (P = .60). CONCLUSIONS: BMCT is a potential option in CLI patients who are not candidates for bypass or endovascular intervention. Limb salvage is unexpectedly high in this population with few other options.
OBJECTIVE: Bone marrow cell therapy (BMCT) for patients with critical limb ischemia (CLI) is a potential treatment in candidates with poor options for standard revascularization procedures. Whereas clinical trials are ongoing, there are few comparative data to assess its efficacy compared with bypass. METHODS:Patients with poor revascularization options underwent BMCT between 2011 and 2013. Outcomes were compared with those of a cohort of CLI patients undergoing infrainguinal bypass thought to be at high risk for graft failure (tissue loss, a tibial target, and a previous endovascular treatment or bypass). BMCTpatients underwent harvest of bone marrow that was then concentrated and injected intramuscularly into the ischemic limb. RESULTS: There were 20 BMCTpatients and 35 high-risk bypass patients. All BMCTpatients had either rest pain (80%) or tissue loss (80%). The majority (65%) had a prior intervention (bypass, 30%; endovascular, 58%) compared with high-risk bypass patients, all of whom had previous revascularization attempts (bypass, 43% [P = .35]; endovascular, 77% [P = .14]). Mean follow-up was 773 days after BMCT and 972 days after high-risk bypass. All patients tolerated BMCT without issues or complications. A second BMCT treatment was performed in 21% because of clinical deterioration. Wound healing occurred in 75% at 1.5 years, including patients receiving second injections, all of which resolved. Rest pain improved in 87.5% of patients. Pain completely resolved in 58% at 1.5 years. Ankle-brachial index improvement was 0.23 (±0.25). Three BMCTpatients went on to amputation. One-year freedom from major amputation or death was 78% for BMCT vs 69% for high-risk bypass (P = .60). CONCLUSIONS:BMCT is a potential option in CLI patients who are not candidates for bypass or endovascular intervention. Limb salvage is unexpectedly high in this population with few other options.
Authors: Mark D Iafrati; John W Hallett; George Geils; Gregory Pearl; Alan Lumsden; Eric Peden; Dennis Bandyk; K S Vijayaraghava; R Radhakrishnan; Enrico Ascher; Anil Hingorani; Sean Roddy Journal: J Vasc Surg Date: 2011-10-21 Impact factor: 4.268
Authors: Randall W Franz; Kaushal J Shah; Jason D Johnson; Richard H Pin; Alan M Parks; Thomas Hankins; Jodi F Hartman; Michelle L Wright Journal: Vasc Endovascular Surg Date: 2011-06-12 Impact factor: 1.089
Authors: Richard J Powell; Anthony J Comerota; Scott A Berceli; Raul Guzman; Timothy D Henry; Edith Tzeng; Omaida Velazquez; William A Marston; Ronnda L Bartel; Amy Longcore; Theresa Stern; Sharon Watling Journal: J Vasc Surg Date: 2011-07-31 Impact factor: 4.268
Authors: Richard J Powell; William A Marston; Scott A Berceli; Raul Guzman; Timothy D Henry; Amy T Longcore; Theresa P Stern; Sharon Watling; Ronnda L Bartel Journal: Mol Ther Date: 2012-03-27 Impact factor: 11.454
Authors: Richard J Powell; Michael Simons; Farrel O Mendelsohn; George Daniel; Timothy D Henry; Minako Koga; Ryuichi Morishita; Brian H Annex Journal: Circulation Date: 2008-06-16 Impact factor: 29.690
Authors: Eric Benoit; Thomas F O'Donnell; Mark D Iafrati; Enrico Asher; Dennis F Bandyk; John W Hallett; Alan B Lumsden; Gregory J Pearl; Sean P Roddy; Krishnaswami Vijayaraghavan; Amit N Patel Journal: J Transl Med Date: 2011-09-27 Impact factor: 5.531
Authors: Michael S Conte; Patrick J Geraghty; Andrew W Bradbury; Nathanael D Hevelone; Stuart R Lipsitz; Gregory L Moneta; Mark R Nehler; Richard J Powell; Anton N Sidawy Journal: J Vasc Surg Date: 2009-11-07 Impact factor: 4.268
Authors: S Keisin Wang; Linden A Green; Natalie A Drucker; Raghu L Motaganahalli; Andres Fajardo; Michael P Murphy Journal: J Vasc Surg Date: 2018-02-01 Impact factor: 4.268
Authors: Pavel I Makarevich; Maria A Boldyreva; Evgeny V Gluhanyuk; Anastasia Yu Efimenko; Konstantin V Dergilev; Evgeny K Shevchenko; Georgy V Sharonov; Julia O Gallinger; Polina A Rodina; Stepan S Sarkisyan; Yu-Chen Hu; Yelena V Parfyonova Journal: Stem Cell Res Ther Date: 2015-10-26 Impact factor: 6.832